Symptomatic Therapy for Patients With Huntington's Disease

• Register: ClinicalTrials.gov
• Last refreshed on: 12 April 2021
• Main ID: NCT04071639
• Date of registration: 26/08/2019
• Prospective Registration: Yes
• Primary sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Public title: Symptomatic Therapy for Patients With Huntington's Disease
• Scientific title: Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients
• Date of first enrolment: March 12, 2020
• Target sample size: 60
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT04071639
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

China

Contacts

• Name: Zhi-Ying Wu, MD&PhD

• Name: Zhi-Ying Wu, MD

• Name: Zhi-Ying Wu
• Affiliation: Second affiliated Hospital, Zhejiang University School of Medicine

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Genetic diagnosis of Huntington's disease

2. Symptomatic patients with Huntington's disease

3. Disease duration less than 5 years -

Exclusion Criteria:

(1) Movement disorder due to other definite causes instead of Huntington's disease (2)
Severe Lung, kidney or liver disease (3) Neoplastic Disease

-



Age minimum: N/A
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Huntington Disease

Intervention(s)

Drug: Deutetrabenazine Oral Tablet [Austedo]

Drug: Haloperidol 2Mg Tab

Drug: Idebenone

Drug: Zoloft 50Mg Tablet

Drug: Risperidone 1Mg Tab

Primary Outcome(s)

The Unified Huntington's Disease Rating Scale [Time Frame: Five years]

Secondary Outcome(s)

Brain MRI [Time Frame: Five years]

Secondary ID(s)

2019238

Source(s) of Monetary Support

Please refer to primary and secondary sponsors